________________________________________________________________________________________________________________________________

(C) Private 2009 - Ruth McKernanIt really started last year ...

September 2009. In 2008 Pfizer engaged rather late in regenerative medicine. Its unit (former Pfizer Technologies) at Sandwich and Abington (UK) matured into Neusentis under the leadership of Dr. Ruth McKernan, the Chief Scientific Officer since its beginnings. In the exclusive interview published only here, she addressed central issues in the development of stem cell therapies.

Several years later most of the basic challenges are still waiting to be resolved by those in the field, for example the complementary roles of small molecules and stem cell biologics in personalized medicine, the standardisation of stem cells for pharmaceutical use, or predictive toxicology to ensure drug safety. Read also about competitors in the field like Novo Nordisk, Cellartis (today: Cellectis), or Cellular Dynamics.

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, today Head of Global Research and Early Development for Merck Serono on stem cell research

Leroy Hood: Thinking Further about Stem Cells

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Drug Testing with Embryonic Stem Cells
- Towards standards for assays

Boehringer Ingelheim: We are obliged to more and more move away from animal models
Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding.
Johan Bottermman, Head of Product Research - Bayer CropScience NV